Compare TMC & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TMC | FATE |
|---|---|---|
| Founded | 2011 | 2007 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 131.5M |
| IPO Year | N/A | 2013 |
| Metric | TMC | FATE |
|---|---|---|
| Price | $7.42 | $1.11 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $6.94 | $3.92 |
| AVG Volume (30 Days) | ★ 9.5M | 1.2M |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,137,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.72 | $0.66 |
| 52 Week High | $11.35 | $2.31 |
| Indicator | TMC | FATE |
|---|---|---|
| Relative Strength Index (RSI) | 56.98 | 50.19 |
| Support Level | $6.26 | $1.03 |
| Resistance Level | $8.14 | $1.16 |
| Average True Range (ATR) | 0.59 | 0.07 |
| MACD | 0.17 | 0.01 |
| Stochastic Oscillator | 77.23 | 76.30 |
TMC The Metals Co Inc is a deep-sea minerals exploration company focused on the collection, processing, and refining of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone (CCZ). Polymetallic nodules are discrete rocks that sit unattached to the seafloor, occur in notable quantities in the CCZ, and have high concentrations of nickel, copper, cobalt, and manganese in a single rock. The company believes these four metals contained in the polymetallic nodules are critical for energy infrastructure and industrial manufacturing. The Company's business consists of only one operating segment, namely exploration of seafloor polymetallic nodules, which includes the development of a metallurgical process to treat such seafloor polymetallic nodules.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.